Document is current
Any future updates will be listed below
-
Authors
Duane, Brett https://orcid.org/0000-0001-9670-0594
Steinbach, Ingeborg https://orcid.org/0000-0002-6326-9651
Stancliffe, Rachel https://orcid.org/0000-0002-1772-2857
Barna, Stefi https://orcid.org/0000-0002-9017-4375
Cameron, David
de Barbieri, Ilaria https://orcid.org/0000-0002-7006-0733
Noruisiene, Edita
Mortimer, Frances
Gerritsen, Karin https://orcid.org/0000-0002-1917-6255
Vanholder, Raymond https://orcid.org/0000-0003-2633-1636
Donati, Gabriele https://orcid.org/0000-0001-8549-1221
Alfano, Gaetano https://orcid.org/0000-0003-0591-8622
Malyszko, Jolanta https://orcid.org/0000-0001-8701-8171
Ligabue, Giulia https://orcid.org/0000-0002-0043-2300
Johnston, Bridget
Wratten, Mary Louise https://orcid.org/0009-0009-9540-7367
Caiazzo, Marialuisa
Schmid, Elisabeth https://orcid.org/0000-0003-4077-365X
Ortiz, Alberto https://orcid.org/0000-0002-9805-9523
-
Funding
Funding for this research was provided by:
HORIZON EUROPE Health (101137054)
- License Information
-
More Information
Article History
Received: 29 April 2024
Accepted: 16 September 2024
First Online: 8 November 2024
Declarations
:
: Alberto Ortiz has received grants from Sanofi and consultancy or speaker fees or travel support from Adviccene, Alexion, Astellas, Astrazeneca, Amicus, Amgen, Boehringer Ingelheim, Fresenius Medical Care, GSK, Bayer, Sanofi-Genzyme, Menarini, Mundipharma, Kyowa Kirin, Lilly, Freeline, Idorsia, Chiesi, Otsuka, Novo-Nordisk, Sysmex and Vifor Fresenius Medical Care Renal Pharma and Spafarma and is Director of the Catedra UAM-Astrazeneca of chronic kidney disease and electrolytes. He has stock in Telara Farma. AO research is also funded by Instituto de Salud Carlos III (ISCIII) FIS/Fondos FEDER RICORS program to RICORS2040 (RD21/0005/0001) funded by European Union – NextGenerationEU, Mecanismo para la Recuperación y la Resiliencia (MRR), COST Action PERMEDIK CA21165, supported by COST (European Cooperation in Science and Technology); PREVENTCKD Consortium Project ID: 101101220 Programme: EU4H DG/Agency: HADEA. Raymond Vanholder is advisor to AstraZeneca, Glaxo Smith Kline, Fresenius Kabi, Novartis, Kibow, Baxter, Nipro, Fresenius Medical Care and Nextkidney. Gabriele Donati has received consultancy fees from Medtronic, speaker fees from Mozarc Medical, Fresenius Medical Care, BBraun. He also received grants from Nipro and Alexion. Karin Gerristen has received consultancy fees from Nextkidney. KG has received funding from the Dutch Growth Fund program NXTGEN HIGHTECH. Mary Lou Wratten is a full-time employee of Mozarc Medical/Bellco. Brett Duane has received consultancy or speaker fees from Proctor and Gamble, Tepe, private dental clinics, as well as other dental companies. There are no other competing interests.
: It does not apply to the present manuscript.
: It does not apply to the present manuscript.
